Diamond Chemical Co. in East Rutherford, NJ, made OTC hand sanitizers without required ingredient and finished-product testing or process validation.
What happened
FDA inspected Diamond Chemical's drug manufacturing facility at Union Avenue & Dubois Street, East Rutherford, New Jersey, from May 6 to 16, 2024. Investigators found the firm never ran an identity test on each lot of ethanol, its active ingredient, and relied on supplier certificates of analysis it had not verified; because the ethanol test was skipped, the firm had no check for methanol, a hazardous impurity. FDA also found no per-batch testing of finished product for ethanol identity and strength, no process validation, no cleaning validation for equipment shared with industrial detergents, and no adequate stability program. FDA called the firm's May 30, 2024 response inadequate.
What FDA found
The firm did not run an identity test on each shipment of each lot of components, including its active ingredient ethanol, and did not verify the reliability of its suppliers' test results.
21 CFR 211.84(d)(1) and 211.84(d)(2)The firm did not test each finished batch for the identity and strength of ethanol before releasing it.
21 CFR 211.165(a)The firm did not validate the manufacturing processes for its hand sanitizer products, and testing alone does not prove a process is validated.
21 CFR 211.100(a)The firm had no cleaning validation for equipment shared between drug products and non-drug products such as industrial dish and laundry detergents.
21 CFR 211.100(a)The firm had no adequate ongoing stability program to show its hand sanitizers stay within specifications through their shelf life.
21 CFR 211.166(a)
What FDA wants
FDA asks the firm to respond in writing within 15 working days with what it has done to fix the violations and prevent recurrence. It also asks the firm to clarify whether it will keep making drugs anywhere, list all drug products it made, notify FDA before resuming, and, if it resumes, engage a qualified CGMP consultant to do a six-system audit.
Who should pay attention
- brands and retailers that buy hand sanitizer or antiseptic soap from this contract manufacturer
- firms that rely on supplier certificates of analysis instead of testing incoming ethanol
- companies that run drug and non-drug products on the same equipment
This is a summary. Read the original letter on fda.gov.